申请人:Guo Liangqin
公开号:US20120264777A1
公开(公告)日:2012-10-18
Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
结构式I的贝塔-咔啉衍生物是生长抑素亚型受体3(SSTR3)的选择性拮抗剂,可用于治疗2型糖尿病以及与该疾病常见相关的病症,包括高血糖、胰岛素抵抗、肥胖、脂质代谢紊乱和高血压。这些化合物也可用于治疗抑郁症和焦虑症。